Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
07/2003
07/31/2003US20030144510 Preparation of pharmaceutical salts
07/31/2003US20030144492 Anticancer agents; central nervous system disorders; antiinflammatory agents
07/31/2003US20030144486 Monoclonal human natural antibodies
07/31/2003US20030144485 Monoclonal human natural antibodies
07/31/2003US20030144482 Diagnosis of skin cancer; vaccine
07/31/2003US20030144474 T cell receptor and a biologically active polypeptide with different recognition biding sites connected by a peptide linker; designed to redirect the immune system against various diseases
07/31/2003US20030144347 Method for treating autoimmune disease
07/31/2003US20030144337 Pyrazole-derived kinase inhibitors and uses thereof
07/31/2003US20030144335 Nitroimidazole compound for allergic conjunctivitis or allergic rhinitis
07/31/2003US20030144334 Cyclopentabenzofuran derivatives and their use
07/31/2003US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4
07/31/2003US20030144323 Phenylalkynes
07/31/2003US20030144309 Inhibitors of Src and other protein kinases
07/31/2003US20030144307 2,6-Disubstituted 7-oxopyrido(2,3-d)pyrimidines; inhibitors of protein kinases; treating diseases mediated by the pro-inflammatory cytokines, e.g., tumor necrosis factor, inter-leukins, cycloxygenase; chronic obstructive pulmonary disease
07/31/2003US20030144302 Process for making substituted pyrazoles
07/31/2003US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
07/31/2003US20030144298 Therapeutic combinations of antihypertensive and antiangiogenics agents
07/31/2003US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives
07/31/2003US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis
07/31/2003US20030144283 Amide substituted imidazoquinolines
07/31/2003US20030144281 Substituted benzimidazole compounds
07/31/2003US20030144279 5-Heterocyclo-pyrazoles
07/31/2003US20030144276 Heterocycle-containing carboxylic acid derivative and drug containing the same
07/31/2003US20030144275 Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis
07/31/2003US20030144267 Novel compounds
07/31/2003US20030144266 Pyrazolo-triazolo- pyrimidine, triazolo-triazolo-pyrimidine and imidazolo-triazolo-pyrimidine derivatives useful for the treatment of hypertension, inflammation, mast cell degranulation, cardiac hypoxia, and ischemia
07/31/2003US20030144247 Obtained by reacting polyalkylene glycol or a reactive derivative, a phospholipid and a drug with each other to form covalent bonds to form a delivery substance
07/31/2003US20030144239 Expression system
07/31/2003US20030144232 Expression system
07/31/2003US20030144217 Prodrugs of aspartyl protease inhibitors
07/31/2003US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence
07/31/2003US20030143739 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof
07/31/2003US20030143695 Novel polypeptide and dna thereof
07/31/2003US20030143690 Peptides and proteins that effect protein phosphorylation; genetic engineered DNA; useful for therapy and diagnosis
07/31/2003US20030143685 Nucleic acid expression control sequence cassettes comprising a stable bacteriophage T5 promoter and nucleic acid regulatory sequences, useful for generating stable expressin vectors of high-level protein expression; culture product
07/31/2003US20030143684 Combining a compound to be tested, a host cell expressing a recombinant protein containing a mammalian C-C chemokine receptor 3 and a ligand for binding of ligand to such receptor, detecting the formation of a receptor-ligand complex
07/31/2003US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin
07/31/2003US20030143633 Factors participating in degranulation of mast cells, dnas encoding the same, method of screening of these factors and the inhibitors
07/31/2003US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening
07/31/2003US20030143622 Human RNA binding proteins
07/31/2003US20030143620 Carbohydrate ligands specific for MHC molecules
07/31/2003US20030143611 Cloning the DNA sequence encoding recombinant SRTA-70 proteins
07/31/2003US20030143589 Drug metabolizing enzymes
07/31/2003US20030143588 Phosphodiesterases
07/31/2003US20030143559 A modified estrogen receptor alpha ligand binding domain containing an amino acid modification in region 1, at region 2, or atleast one amino acid modifiation in both of regions, and these domain interacts with a nonendogenous ligand
07/31/2003US20030143281 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof
07/31/2003US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection
07/31/2003US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases
07/31/2003US20030143245 Multivalent streptococcal vaccine compositions and methods for use
07/31/2003US20030143243 Compounds and methods for immunotherapy and diagnosis of tuberculosis
07/31/2003US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway
07/31/2003US20030143221 Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant
07/31/2003US20030143209 For gene therapy of cancers or cardiovascular conditions
07/31/2003US20030143197 Administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal
07/31/2003US20030143192 Chemokine beta-7
07/31/2003US20030143190 For modulating the immune system; therapy of cancer
07/31/2003US20030143185 Polymer conjugates of protein kinase C inhibitors
07/31/2003CA2510751A1 Multimers of receptor-binding ligands
07/31/2003CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar
07/31/2003CA2474623A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof
07/31/2003CA2474292A1 Sustained release pharmaceutical composition
07/31/2003CA2474201A1 Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunsuppressor and anti-inflammatory agent
07/31/2003CA2474077A1 Methods for treatment of multiple sclerosis with statins
07/31/2003CA2473829A1 Use of tgf-.beta. antagonists to treat or to prevent chronic transplant rejection
07/31/2003CA2473781A1 Glycoisoforms of adiponectin and uses thereof
07/31/2003CA2473740A1 Methods of treating conditions associated with an edg receptor
07/31/2003CA2473717A1 Dna dosage forms
07/31/2003CA2473707A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
07/31/2003CA2473490A1 Peptide-carrying bodies for immune response
07/31/2003CA2473395A1 Phospholipid bodies and use thereof in medical treatment
07/31/2003CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators
07/31/2003CA2472367A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
07/31/2003CA2471740A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies
07/31/2003CA2471342A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
07/30/2003EP1331007A2 Chinese herbs extract
07/30/2003EP1331002A2 Oil-free pharmaceutical compositions containing cyclosporin A
07/30/2003EP1330538A2 Cd36 as a heat shock protein receptor and uses thereof
07/30/2003EP1330535A2 Kini-3 motor protein and methods for its use
07/30/2003EP1330468A1 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
07/30/2003EP1330467A2 Modified, hydroxy-substituted aromatic structures having cytoprotective activity
07/30/2003EP1330459A2 Triptolide analogs for the treatment of autoimmune and inflammatory disorders
07/30/2003EP1330455A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
07/30/2003EP1330453A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents
07/30/2003EP1330448A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
07/30/2003EP1330447A2 Peptides as met-ap2 inhibitors
07/30/2003EP1330439A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine
07/30/2003EP1330436A1 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3-3 receptor antagonists
07/30/2003EP1330430A2 Integrin receptor inhibitors
07/30/2003EP1330293A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
07/30/2003EP1330264A2 Vaccine for treating allergy
07/30/2003EP1330263A2 Method for down-regulating ige
07/30/2003EP1330241A2 Use of tolterodine to treat asthma
07/30/2003EP1187817B1 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
07/30/2003EP1184388B1 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof
07/30/2003EP1082962B1 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors nf-(k)b
07/30/2003EP0983074B1 Non-myeloablative tolerogenic treatment
07/30/2003EP0975362B1 Pharmaceutical or food composition for treating pathologies related to graft versus host, allergic or autoimmune reaction
07/30/2003EP0946541B1 Quinolines and their therapeutic use
07/30/2003EP0941067B1 Stable glassy state powder formulations
07/30/2003EP0859628B1 Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites
1 ... 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 ... 1172